Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Change in Accured Expenses (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Change in Accured Expenses for 13 consecutive years, with -$88.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 1301.7% to -$88.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $131.9 million, a 279.96% increase, with the full-year FY2025 number at $131.9 million, up 279.96% from a year prior.
  • Change in Accured Expenses was -$88.4 million for Q4 2025 at Madrigal Pharmaceuticals, down from $187.5 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $187.5 million in Q3 2025 to a low of -$88.4 million in Q4 2025.
  • A 5-year average of $10.6 million and a median of $2.8 million in 2021 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 1712.96% in 2024, then plummeted 1301.7% in 2025.
  • Madrigal Pharmaceuticals' Change in Accured Expenses stood at -$3.5 million in 2021, then skyrocketed by 443.56% to $11.9 million in 2022, then tumbled by 37.87% to $7.4 million in 2023, then crashed by 185.59% to -$6.3 million in 2024, then tumbled by 1301.7% to -$88.4 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Change in Accured Expenses are -$88.4 million (Q4 2025), $187.5 million (Q3 2025), and $33.3 million (Q2 2025).